Entero Healthcare Solutions LtdQ1 FY27
Entero Healthcare Solutions Ltd Q1 FY27 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Price: ₹1,754P/E: 48.0Market Cap: ₹6.2K CrSector: Retailing
Management growth scorecard
Revenue
Category 2
Margin
Category 2
Fundraise
N/A
Order
N/A
Capex
Yes
1 of 3 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 2- →Entero Healthcare Solutions targets consolidated revenue growth of approximately 23% year-on-year for FY27, excluding any major new acquisitions.
- →The company aims to grow at an excess of 20% over the medium term (3 to 4 years), combining both organic and inorganic growth.
- →Focus for FY27 is primarily on organic growth by deepening existing relationships and expanding wallet share with current customers.
- →MedTech revenue is expected to cross INR 1,000 crores organically in FY27, contributing higher margins and growth.
- →Growth outperforming the industry (IPM) is driven by better service levels, wider product range, and stronger collaborations.
- →No major inorganic deals are planned in FY27, though small acquisitions may happen.
- →Long term vision targets sustained double-digit base growth and market share gains through industry consolidation.
Margin guidance
Category 2- →Entero Healthcare projects a consolidated revenue growth of approximately 23% year-on-year for FY27, with a 5% EBITDA margin and 50% EBITDA to operating cash flow conversion.
- →Over the medium term (3-4 years), the company targets growth exceeding 20% annually, driven primarily by organic growth.
- →EBITDA margins are expected to expand beyond 5%, with internal aspirations to exceed 6% due to operating leverage and procurement efficiencies.
- →Profit after tax (PAT) saw substantial growth in Q1, with a PAT margin of 2.7%; the company is focused on sustaining and building on this margin.
- →Return on capital employed (ROCE) and return on equity (ROE) are expected to improve, with ROCE projected in the 25-30% range over 3-4 years.
- →Incremental working capital needs are expected to be met internally, enabling potential debt reduction or further acquisitions to boost PAT.
- →MedTech segment growth, crossing INR 1,000 crores in FY27, is a major driver of margin expansion.
Fundraise plans
- →There is no explicit mention of new fundraising through debt or equity in the current quarter.
- →The company has INR200 crores of debt taken primarily for recent acquisitions, with full interest impact seen in Q1.
- →Future deployment of cash flow (after converting 50% of EBITDA to operating cash flow) may include acquisition funding, debt repayment, or minority buyouts based on what improves EPS the most.
- →No major acquisitions are planned in the near term, focusing on organic growth instead.
- →Acquisition funding and minority buyout funding can come from the parent or subsidiaries, with flexible options available.
- →Management remains open to compelling acquisition opportunities, especially towards the last quarter of the financial year.
- →Deferred decisions on interest costs and operational expenses over the year may influence future capital needs.
Order book
The provided pages from the PDF "1284670.pdf" do not explicitly mention the current or expected order book or pending orders for Entero Healthcare Solutions Limited. However, based on the discussion:
- The company is focused on organic growth with no major acquisitions planned for FY27.
- They maintain a strong and expanding distribution network with over 72,000 retail customers and 2,300 hospital customers.
- They have significant collaborations and partnerships expanding demand generation, especially in the MedTech segment.
- There is mention of government contracts, which saw some preponement of billing in last quarter, indicating ongoing government projects.
- The company aims for approximately 23% revenue growth in FY27, implying a healthy order inflow to support this.
No specific quantitative data on current or expected order book or pending orders is disclosed in the transcript.
Capex plans
Yes- →No explicit mention of major capex or strategic investments planned for FY27.
- →Management indicates there will not be any major acquisitions in FY27 but keeps options open for smaller deals.
- →Cash generated (50% of EBITDA converted to operating cash flow after working capital) will be deployed either for acquisitions, debt reduction, or buying out minority interests, whichever best enhances EPS.
- →Depreciation levels are expected to remain steady going forward, subject to no major capex.
- →Management emphasizes focusing on organic growth and improving existing business rather than large-scale inorganic expansion currently.
- →Opportunities for minor business exits or reducing low-margin businesses exist but will first be attempted to improve margins before letting go.
Track Entero Healthcare Solutions Ltd — get its next earnings analysis in your feed
Margin guidance
Category 2- →Entero Healthcare projects a consolidated revenue growth of approximately 23% year-on-year for FY27, with a 5% EBITDA margin and 50% EBITDA to operating cash flow conversion.
- →Over the medium term (3-4 years), the company targets growth exceeding 20% annually, driven primarily by organic growth.
- →EBITDA margins are expected to expand beyond 5%, with internal aspirations to exceed 6% due to operating leverage and procurement efficiencies.
- →Profit after tax (PAT) saw substantial growth in Q1, with a PAT margin of 2.7%; the company is focused on sustaining and building on this margin.
- →Return on capital employed (ROCE) and return on equity (ROE) are expected to improve, with ROCE projected in the 25-30% range over 3-4 years.
- →Incremental working capital needs are expected to be met internally, enabling potential debt reduction or further acquisitions to boost PAT.
- →MedTech segment growth, crossing INR 1,000 crores in FY27, is a major driver of margin expansion.
Order book
The provided pages from the PDF "1284670.pdf" do not explicitly mention the current or expected order book or pending orders for Entero Healthcare Solutions Limited. However, based on the discussion:
- The company is focused on organic growth with no major acquisitions planned for FY27.
- They maintain a strong and expanding distribution network with over 72,000 retail customers and 2,300 hospital customers.
- They have significant collaborations and partnerships expanding demand generation, especially in the MedTech segment.
- There is mention of government contracts, which saw some preponement of billing in last quarter, indicating ongoing government projects.
- The company aims for approximately 23% revenue growth in FY27, implying a healthy order inflow to support this.
No specific quantitative data on current or expected order book or pending orders is disclosed in the transcript.
How does Entero Healthcare Solutions Ltd rank vs peers in Retailing?
Pro feature1Entero Healthcare Solutions Ltd
Rev 2Mar 2
See full Retailing sector rankings
How does Entero Healthcare Solutions Ltd rank in Retailing?
Compare Entero Healthcare Solutions Ltd against every Retailing company (Q1 FY27) on revenue, margins and earnings-call signals.